$IVF Balance Sheet | Understand Stock

$IVF

$0.54 -$0.02 (3.6%) Close

$IVF Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
ASSETS
Current assets
Cash
Accounts receivable, net of allowances of $110,871 and $69,641 as of June 30, 2026 and December 31, 2025, respectively
Inventory, net of allowances of $40,000 and $0 as of June 30, 2026 and December 31, 2025, respectively
Prepaid expenses and other current assets
Current assets held for disposition
Total current assets
Property and equipment, net
Capitalized patents, net
Lease right of use
Trademarks
Notes receivable from joint ventures
Intangible assets, net
Goodwill
Investment in joint ventures
Equity investments
Investment in NAYA
Investment in NAYA Therapeutics
Note receivable
Nonrelated Party
Related Party
Total note receivable
Noncurrent assets held for disposition
Total assets

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable and accrued liabilities, including related parties
Related Party
Total accounts payable and accrued liabilities, including related parties

Accounts payable and accrued liabilities
Accrued compensation
Convertible notes payable
Nonrelated Party
Related Party
Total convertible notes payable
Notes payable
Nonrelated Party
Related Party
Total notes payable

Convertible notes, net
Notes payable - related party, net
Deferred revenue
Lease liability, current portion
Additional payments for acquisition, current portion
Warrant liability
Other current liabilities
Current liabilities held for disposition
Total current liabilities

Lease liability, net of current portion
Deferred revenue, net of current portion
Liability for excess losses of equity method investee
Notes payable – net of current portion
Deferred tax liability
Other liabilities, net of current portion
Additional payments for acquisition, net of current portion
Total liabilities

Series C-2 Preferred Stock (mezzanine) $1,000.00 par value; 20,000 shares authorized; 3,004 and 8,576 issued and outstanding as of December 31, 2025 and 2024, respectively.
Series C-2 Preferred Stock
Series C-1 Preferred Stock
Total series C-2 Preferred Stock (mezzanine) $1,000.00 par value; 20,000 shares authorized; 3,004 and 8,576 issued and outstanding as of December 31, 2025 and 2024, respectively.
Stockholders’ equity
Preferred stock, value
Series A Preferred Stock
Series B Preferred Stock
Series C-1 Preferred Stock
Series C-2 Preferred Stock
Series D Preferred Stock
Common Stock, $.0001 par value; 50,000,000 shares authorized; 2,295,035 and 477,366 issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
Additional paid-in capital
Accumulated deficit
Noncontrolling interest
Total stockholders’ equity
Total liabilities and stockholders’ equity

Comments